BioSpace News Archive

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces that the primary endpoint was met in two Chinese registration studies of recombinant full-human anti-PCSK-9 monoclonal antibody.

Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company’s investigational new drug (IND) application to conduct human studies using Resolv ER™ for the treatment of Vitreomacular Attachment (VMA).

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach (“EARTH”) efficacy trial conducted by Regencell Bioscience Asia Limited (“Regencell Asia”) of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation).

CANbridge Pharmaceuticals, Inc. announced that it has appointed Lan Hu, Ph.D. as the independent, nonexecutive Director of the Board of Directors and member of the remuneration committee, effective as of February 16, 2022.

Stella Diagnostics, Inc. announced its STLA101 mass spec proteomic assay was selected as the winner of the “Best Clinical Proteomics Solution of the Year” award for 2021 in the inaugural awards program conducted by BioTech Breakthrough.

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors.

Skye Bioscience, Inc. announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100.

Tesis Biosciences has acquired Genome Explorations, a premier research institution providing global genomic profiling and molecular diagnostics services.

PharmaEssentia USA Corporation announced the appointment of two executives to the company’s US leadership team: Anjana Pursnani.

Jaguar Health, Inc. announced that it has submitted a request to the U.S. Food and Drug Administration’s Center for Veterinary Medicine for Minor Use/Minor Species designation for the company’s oral plant-based drug candidate Canalevia™ for treatment of exercise-induced diarrhea in dogs.